Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Poster - [In-Person Posters Tues] Drug Development: Human
  • Poster
  • Safety Of Oral ALZ-801 In APOE4/4 And APOE3/4 Subjects With Early AD In Long-term Extension Studies Up To 4 Years [Board No. Tuesday-0039]
  • Board no. Tuesday-0039
    Set Timezone

Aidan Power, MD1, Susan Abushakra, MD1, John A. Hey, PhD1, David Watson2, Emer MacSweeney, BSc (Hons), MRCP, FRCR3, Sharon Cohen4, Jakub Hort5, Neils Prins, MD PHD6, Anton Porsteinsson7, Marwan Sabbagh, MD8, Earvin Liang1, Susan Flint1, Patrick Kesslak, PhD1, Adem Albayrak1, Martin Tolar, MD PHD1;
1Alzheon, Framingham, MA, USA, 2Alzheimer’s Research and Treatment Center, Wellington, FL, USA, 3ReCognition Health, London, United Kingdom, 4Toronto Memory Program, Toronto, ON, Canada, 5Charles University and Motol University Hospital, Prague, Czech Republic, 6Brain Research Center, Amsterdam, Netherlands, 7University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, 8Barrow Neurological Institute, Neurology, Phoenix, AZ, USA
Types
Main Session